The article presents abstracts of clinical trials for non-small cell lung cancer (NSCLC) including the improvement of objective response rate (ORR) from nanoparticle albumin-bound paclitaxel plus carboplatin (nab-P/C), the efficacy and safety of nab-P/C, and the analysis of symptoms of neuropathy with nab-P/C.